Political Interference with CDC and FDA During COVID-19: Edited Scientific Reports and Hydroxychloroquine Pressure
Tier 3Documented2020-01-01 to 2020-12-31
Factual Summary
Throughout 2020, the Trump administration exerted political pressure on the Centers for Disease Control and Prevention and the Food and Drug Administration in ways that undermined the scientific independence of both agencies during the COVID-19 pandemic.
Political appointees at the Department of Health and Human Services intervened in the CDC's Morbidity and Mortality Weekly Reports, the agency's primary vehicle for communicating scientific findings to the public. Paul Alexander, a senior adviser to HHS Assistant Secretary for Public Affairs Michael Caputo, sent repeated emails to CDC officials demanding changes to MMWR reports that he considered politically damaging to President Trump. Alexander sought to soften findings about COVID-19 transmission among children, arguing in emails that the reports could undermine the administration's push to reopen schools. Internal emails obtained through congressional investigations showed that Alexander and Caputo succeeded in altering or delaying the release of at least five scientific reports. In a September 2020 email, Alexander told Caputo that he had successfully changed the opening line of a CDC report about COVID-19 transmission in children.
A House Select Subcommittee on the Coronavirus Crisis investigation found that HHS political appointees attempted to influence at least 19 different MMWR reports, seeking to change publication processes, manipulate content, or block dissemination of findings they deemed harmful to the president. CDC Director Robert Redfield later acknowledged to congressional investigators that political pressure had been applied but disputed whether it had materially altered the reports' conclusions.
Separately, Dr. Rick Bright, the director of the Biomedical Advanced Research and Development Authority, filed a formal whistleblower complaint in May 2020 alleging that HHS leadership had pressured BARDA to promote the widespread use of hydroxychloroquine and chloroquine as COVID-19 treatments, despite insufficient evidence of their efficacy and safety. Bright stated that he was removed from his position and reassigned to a lesser role at the National Institutes of Health after he resisted pressure to expand access to the drugs without proper clinical evaluation. The U.S. Office of Special Counsel found "reasonable grounds to believe" that HHS had unlawfully retaliated against Bright in violation of the Whistleblower Protection Act. Bright resigned from the federal government in October 2020.
The FDA faced its own political pressures during this period. The agency granted an Emergency Use Authorization for hydroxychloroquine in March 2020, which it subsequently revoked in June 2020 after clinical data showed the drug was unlikely to be effective against COVID-19 and posed cardiac risks. In August 2020, the FDA issued an EUA for convalescent plasma therapy, a decision that FDA Commissioner Stephen Hahn later acknowledged had overstated the treatment's benefits. Senior FDA officials reportedly considered resigning over concerns about political interference with the authorization process.
Primary Sources
1. House Select Subcommittee on the Coronavirus Crisis: Report on Trump administration interference with CDC MMWR reports, October 2022
2. U.S. Office of Special Counsel determination on Rick Bright whistleblower complaint, May 2020
3. Rick Bright whistleblower complaint, filed May 5, 2020
4. FDA Emergency Use Authorization for hydroxychloroquine (March 2020) and revocation (June 2020)
Corroborating Sources
1. CNN: "Trump's HHS alters CDC documents for political reasons, official says," September 12, 2020
2. CNBC: "Trump officials bragged about pressuring CDC to alter Covid reports, emails reveal," April 9, 2021
3. Washington Post: "HHS official Rick Bright alleges he was demoted for resisting push for hydroxychloroquine," May 5, 2020
4. NPR: "Whistleblower On How Political Pressure Affects Safety Of Coronavirus Vaccines," October 9, 2020
5. CBS News: "Rick Bright, government whistleblower, says the Trump administration's coronavirus response has cost lives," May 14, 2020
Counterarguments and Context
The Trump administration argued that political leadership has a legitimate role in shaping public health messaging and that the communications around CDC reports were standard interagency coordination rather than scientific interference. HHS officials characterized Alexander's emails as suggestions rather than directives and stated that final editorial decisions remained with CDC scientists. Regarding hydroxychloroquine, Trump and his allies argued that the drug showed early promise in limited studies and that in a pandemic emergency, expanding access to a potentially beneficial treatment was appropriate even before large-scale clinical trials were completed. The administration noted that the FDA's Emergency Use Authorization process is designed for exactly such emergencies. Defenders of the administration's approach argued that Bright's reassignment was a routine personnel decision unrelated to his stance on hydroxychloroquine. The Office of Special Counsel's finding of reasonable grounds for retaliation, however, contradicted this characterization. Scientists and public health officials argued that the interference damaged public trust in federal health agencies at a moment when accurate, apolitical scientific communication was essential.
Author's Note
This entry is classified as Tier 3 because the interference is documented through primary evidence, including internal emails obtained through congressional investigation, the formal whistleblower complaint, the Office of Special Counsel's finding of probable retaliation, and the House Select Subcommittee's detailed report. The evidence of political pressure on MMWR reports was acknowledged in part by CDC leadership. No criminal charges resulted from the interference.